

FORM PTO 1449 (modified)

Attorney Docket No. X12383M Serial No 09/744,431

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

Applicants James A. Hoffmann, Jirong Lu

Filing Date January 22, 2001 Group 1647

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
Rm	AK	5,270,057	12/14/1993	Andreas L.J. De Meere, et al.			
	AL	5,384,132	01/24/1995	Andreas L.J. De Meere, et al.			
	AM	4,589,402	05/20/1986	Gary D. Hodgen, et al.			
	AN	4,746,508	05/24/1988	Martin C. Carey, et al.			
	AO	5,945,187	08/31/1999	Thomas Buch-Rasmussen, et al.			
Rm	AP	5,681,822	10/28/1997	Michael Bornstein, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation
							yes no
Rm	BB	EP 0 920 873	12/7/98	EPO			
	BC	EP 0 652 766	7/29/93	EPO			
	BD	GB 839 300	8/25/58	United Kingdom			
	BE	EP 0 448 146	09/25/1991	EPO			
	BF	EP 0 853 945	07/22/1998	EPO			
Rm	BG	WO 93/11788	06/24/1993	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Rm	CX	John G. Pierce & Thomas F. Parsons, "Glycoprotein Hormones: Structure and Function" Ann. Rev. Biochem. 50:465-95 (1981).
	CY	Jacques U. Baenziger & Eric D. Green, "Pituitary Glycoprotein Hormone Oligosaccharides: Structure, Synthesis and Function of the Asparagine-Linked Oligosaccharides on Lutropin, Follitropin, and Thyrotropin" Biochimica et Biophysica Acta 947:287-306 (1988).
	CZ	Vincenta Garcia-Campayo, et al., "Design of Stable Biologically Active Recombinant Lutropin Analogs" Nature Biotechnology 15:663-67 (1997).
	CAA	Richard L. Remmele, Jr., et al., "Interleukin-1 Receptor (IL-1R) Liquid Formulation Development Using Differential Scanning Calorimetry" Pharmaceutical Research 15(2):200-08 (1998).
Rm	CAB	Jonas Fransson, et al., "Solvent Effects on the Solubility and Physical Stability of Human Insulin-Like Growth Factor 1" Pharmaceutical Research 14(3):606-12 (1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

BEST AVAILABLE COPY

FORM PTO 1449 (modified)		Atty. Docket No. X12383M	Serial No 09/744,431
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants James A. Hoffmann, Jirong Lu	
		Filing Date January 22, 2001	Group 1647
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CAC		Xanthe M. Lam, et al., "The Effect of Benzyl Alcohol on Recombinant Human Interferon-?" Pharmaceutical Research 14(6):725-29 (1997).	
CAD		Leo E. Reichert, Jr. & Rosemary B. Ramsey, "Dissociation of Human Follicle-Stimulating Hormone" The Journal of Biological Chemistry 250(8):3034-40 (1975).	
CAE		Judith C. Heikoop, et al., "Structure-based Design and Protein Engineering of Intersubunit Disulfide Bonds in Gonadotropins" Nature Biotechnology 15:658-62 (1997).	
CAF		M.J. Rafferty, et al., "Safety and Tolerability of a Multidose Formulation of Epoetin Beta in Dialysis Patients" Clinical Nephrology. 54(3):240-45 (2000).	
CAG		L.A.M. Frenken, et al., "Analysis of the Efficacy of Measures to Reduce Pain After Subcutaneous Administration of Epoetin Alfa" Nephrology Dialysis Transplantation 9:1295-98 (1994).	
CAH		Jan Trøst Jørgenson, "Improvement of Patient Convenience in Treatment with Growth Hormone" Journal of Pediatric Endocrinology 7(2):175-80 (1994).	
CAI		Nina Vahl, et al., "Bioavailability of Recombinant Human Growth Hormone in Different Concentrations and Formulations" Pharmacology & Toxicology 79:144-49 (1996).	
CAJ		Syed M. Amir, et al., "Phenol, A Potent Stimulator of Adenylate Cyclase in Human Thyroid Membranes" Endocrine Research Communications, 8(2):83-95 (1981).	
CAK		Wendy L. St. Peter, et al., "Pain Comparison After Subcutaneous Administration of Single-Dose Formulation Versus Multidose Formulation of Epogen in Hemodialysis Patients" American Journal of Kidney Diseases, 32(3):470-74 (1998).	
CAL		A.P.L. [®] Injection 5 000 IU and Injection 10 000 IU, http://home.intekom.com/pharm/akromed/apl-inj.html , as of 12/10/2002.	
CAM		Profasi [®] (chorionic gonadotropin for injection, USP) for Intramuscular Injection, package insert revised 1993.	
CAN		Pregnyl [®] (chorionic gonadotropin for injection, USP), http://www.organoninc.com/pi/pregnyl_pi.html , as of 12/10/2002.	
CAO		A.P.L. [®] (chorionic gonadotropin for injection, USP), For Intramuscular Injection Only, Physicians' Desk Reference, 51st Edition, p. 2805 (1997).	
CAP		Pregnyl [®] (chorionic gonadotropin for injection, USP), Physicians' Desk Reference, 51st Edition, p. 1878 (1997).	
CAQ		Profasi [®] (chorionic gonadotropin for injection, USP) for Intramuscular Injection, Physicians' Desk Reference, 51st Edition, pp. 2620-21 (1997).	
CAR		Thomas W. Strickland, et al, "The Kinetic and Equilibrium Parameters of Subunit Association and Gonadotropin Dissociation" The Journal of Biological Chemistry, 257 (6): 2954-2960 (1982).	
EXAMINER	DATE CONSIDERED		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

BEST AVAILABLE COPY